Cargando…
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin lymphoma and particularly, blastic plasmacytoi...
Autores principales: | Testa, Ugo, Pelosi, Elvira, Castelli, Germana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769702/ https://www.ncbi.nlm.nih.gov/pubmed/31547472 http://dx.doi.org/10.3390/cancers11091358 |
Ejemplares similares
-
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
por: Testa, Ugo, et al.
Publicado: (2014) -
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
por: Pelosi, Elvira, et al.
Publicado: (2023) -
Clonal Hematopoiesis: Role in Hematologic and Non-Hematologic Malignancies
por: Testa, Ugo, et al.
Publicado: (2022) -
Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets
por: Testa, Ugo, et al.
Publicado: (2020) -
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
por: Testa, Ugo, et al.
Publicado: (2019)